Scientists have identified the transcription factor DMP1 as a pivotal tumor suppressor for both human and mouse lung cancers, especially in carcinomas that exhibit intact Arf-p53 pathways. The research, published by Cell Press in the October 2007 issue of Cancer Cell, may lead to development of new drug therapies for lung cancer.

A drug to treat colon cancer is proving much more convenient than traditional chemotherapy, has fewer side effects - and a study of almost 2,000 patients has shown it is giving them a better chance of surviving the disease.

The fjords and arctic waters of Norway have become a 'liquid goldmine' for prospecting for the next blockbuster drugs for cancer, AIDS, and other ills, according to an article scheduled for the Oct. 8 issue of Chemical & Engineering News, ACS' weekly newsmagazine.

Researchers have uncovered a new way in which a cell protein protects cancer cells from a wide range of chemotherapeutic drugs, identifying a possible target for improving treatment outcomes for patients.

University of Cincinnati (UC) physician-scientists believe identifying a genetic “fingerprint” could help predict which specific therapies will be most effective for patients with gastric cancer.

A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.

In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped. New research by UC Irvine scientists indicates that Imatinib could cure CML under certain circumstances if it is taken over a long enough period of time.

New clinical data showed an experimental drug called pertuzumab prolonged the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor said recently.

An experimental drug that attacks cancer in an entirely new way has shown promise in treating advanced melanoma, delaying progression of the disease and prolonging the lives of patients.

A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.

A Jekyll-Hyde mechanism that both protects healthy cells and enables cancer cells could be the basis for new cancer-fighting drugs.

Researchers at Dana-Farber Cancer Institute have shown that several, rather than just one, cell-growth switches are simultaneously overactive in many brain tumors and other solid tumors, explaining why treatment with just a single "targeted" switch-blocking drug often yields disappointing results.